New radioactive tracer aims to illuminate hidden prostate cancer
NCT ID NCT07236112
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests TRDC002, a radioactive tracer that attaches to PSMA proteins on prostate cancer cells, to improve PET/CT imaging in patients whose cancer has returned or spread. Six adults with PSMA-positive recurrent or metastatic prostate cancer will receive a single dose of TRDC002 and undergo PET/CT scans. The goal is to find the best dose and timing for clear images, while also checking safety and how the tracer moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TRDC002 (a radioactive tracer using copper-64 to bind to PSMA proteins on prostate cancer cells)
What this could lead to
If successful, this could provide a more accurate imaging method to detect where prostate cancer has spread, helping doctors choose better treatments.
What could go wrong
This is a very early Phase 1 trial with only 6 participants, so results may not apply to all patients. The tracer may not clearly show all cancer spots, and there are unknown safety risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Union Hospital, Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China